Reduced levels of plasmalogens—a class of lipids created in the liver that are integral to cell membranes in the brain—are associated with an increased risk of Alzheimer’s Disease, according to new research presented this week at the Alzheimer’s Association International Conference (AAIC) 2018 by Mitchel A. Kling, MD, an associate professor of Psychiatry in the Perelman School of Medicine at the University of Pennsylvania and the Veterans Affairs Medical Center.
Plasmalogens are created in the liver and are dispersed through the blood stream in the form of lipoproteins, which also transport cholesterol and other lipids to and from cells and tissues throughout the body, including the brain. Kling, and the multi-institutional Alzheimer’s Disease Metabolomics Consortium led by Rima F. Kaddurah-Daouk, PhD, at Duke University School of Medicine, developed three indices for measuring the amount of these lipids related to cognition, in order to identify whether reduced levels in the bloodstream are associated with an increased risk of Alzheimer’s disease, mild cognitive impairment (MCI), overall cognitive function, and/or other biomarkers of neurodegeneration in Alzheimer’s disease. The three indices measured: the ratios of plasmalogens to each other; the ratios of plasmalogens to their closely-related, more conventional lipid counterparts; and a combination of these two quantities. Continue reading